Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 63

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 63
---
 and objectives, how our compensation program is designed, the elements of executive compensation, the use of comparisons and peer group data, and the actual compensation of our CEO and other NEOs. The Compensation Committee and our Board of Directors believe that the policies and practices described in the Compensation Discussion and Analysis section of this Proxy Statement are effective in implementing our compensation philosophy and objectives and that the compensation of our CEO and other NEOs for fiscal year 2024 reflects and supports those policies and practices. Our Compensation Committee and Board of Directors will take into consideration the outcome of this advisory vote in determining future compensation decisions. The Board of Directors recommends a vote “FOR” the proposal to approve, on a non-binding basis, the compensation paid to our named executive officers, as described in this Proxy Statement. 48

PROPOSAL 3
RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM The Audit Committee of the Board of Directors has selected KPMG LLP as our independent registered public accounting firm (IRPA Firm) for the fiscal year ending December 31, 2025. The IRPA Firm has served as our independent auditors since October 2015. The IRPA Firm is considered by management to be well qualified. Appointment of the IRPA Firm is not required to be submitted to a vote of our stockholders for ratification. However, the Board of Directors has determined that the matter should be presented to the stockholders as a matter of good corporate practice. If the stockholders fail to ratify the appointment, the Audit Committee will reconsider whether to retain the IRPA Firm and may retain that firm or another without resubmitting the matter to our stockholders. Even if the appointment is ratified, the Audit Committee may, in its discretion, direct the appointment of a different IRPA Firm at any time during the year if it determines that such a change would be in the Company’s best interests and the best interests of the stockholders. A representative from the IRPA Firm is expected to attend the Annual Meeting of Stockholders and will have the opportunity to respond to appropriate questions of stockholders. The following table sets forth, in thousands, the aggregate billed fees and fees expected to be billed for services rendered to us by KPMG LLP through March 31, 2025 as described below ($ in thousands):

| ​                  | ​ | ​ | 2024 |   |       |   | ​ | ​ | 2023 |   |       |   | ​ |
|:-------------------|:--|